Our funders

The NC3Rs has an annual budget of around £10 million. We receive core funding from the Medical Research Council (MRC) and the Biotechnology and Biological Sciences Research Council (BBSRC), both of which are part of UK Research and Innovation (UKRI).

We also receive funding for specific programmes from the charitable and commercial sectors, and co-funding from other research funders. In 2019/20, this includes the following organisations:

Association of the British Pharmaceutical Industry (ABPI)1  

Arthritis Research UK
British Heart Foundation (BHF)
Cancer Research UK (CRUK)
Engineering and Physical Sciences Research Council (EPSRC)
GlaxoSmithKline (GSK)
SCJohnson
Shell
Syngenta
The Dow Chemical Company
Unilever
Wellcome Trust

in accordance with the ABPI's Code of Practice regulating the pharmaceutical industry, the following companies have provided funding to the NC3Rs as part of the ABPI-NC3Rs collaboration: AstraZeneca, Covance Laboratories, Eli Lily & Company, GlaxoSmithKline, Huntingdon Life Sciences,  Novartis Pharmaceuticals, Pfizer, Shire Pharmaceutical Development, Takeda Cambridge and UCB Pharma.


We have six Regional Programme Managers supporting the application of the 3Rs in Universities and Institutes across England and Wales. These posts are co-funded by the organisations they support, namely:

The Francis Crick Institute

Great Western 4 Alliance (University of Bath, University of Bristol, Cardiff University and University of Exeter)

King’s College London

The London School of Hygiene and Tropical Medicine

Royal Veterinary College

University College London

University of Birmingham

University of Leicester

The University of Liverpool

The University of Manchester

University of Nottingham

University of Oxford

The University of Sheffield